Splenic Marginal Zone Lymphoma in Turkey: Association with Hepatitis B Instead of Hepatitis C Virus as an Etiologic and Possible Prognostic Factor - A Multicenter Cohort Study

Autor: Aysegul Uner, Sinem Namdaroglu, Ibrahim Barista, Elif Gungor, Mehmet Hilmi Dogu, Esra Ozhamam, Ilhami Berber, Rahsan Yildirim, Umit Yavuz Malkan, Sinan Demircioğlu, Serdal Korkmaz, Mehmet Sinan Dal, Mufide Okay, Gulsum Akgun Cagliyan, Tuncay Aslan, Yahya Buyukasik, Abdullah Agit, Evren Ozdemir, Ayşe Uysal, Filiz Vural, Serdar Sivgin, Arzu Saglam, Bulent Eser, Esra Yildizhan, Gülsüm Özet, Nevin Alayvaz Aslan, Mehmet Ali Erkurt, Fevzi Altuntaş
Přispěvatelé: Ege Üniversitesi, OMÜ
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
HBsAg
hepatitis b virus
Turkey
medicine.disease_cause
Gastroenterology
Cohort Studies
0302 clinical medicine
risk factors
030212 general & internal medicine
Aged
80 and over
education.field_of_study
Hepatitis C virus
lcsh:Diseases of the blood and blood-forming organs
Hematology
Middle Aged
Hepatitis B
Prognosis
030220 oncology & carcinogenesis
Female
Viral hepatitis
Viral load
Research Article
Adult
Hepatitis B virus
lcsh:Internal medicine
medicine.medical_specialty
Population
Low-grade lymphoma
0-Belirlenecek
03 medical and health sciences
Internal medicine
medicine
Humans
Splenic marginal zone lymphoma
lcsh:RC31-1245
education
Aged
lcsh:RC633-647.5
business.industry
[No Keywords]
Lymphoma
B-Cell
Marginal Zone
hepatitis c virus
medicine.disease
low-grade lymphoma
Risk factors
business
Zdroj: Turkish Journal of Hematology, Vol 37, Iss 2, Pp 84-90 (2020)
Turkish Journal of Hematology
Popis: Objective: Chronic antigenic stimulation is frequently blamed in the pathogenesis of extranodal marginal zone lymphomas including splenic marginal zone lymphoma (SMZL). Chronic hepatitis C is frequently observed in SMZL patients in some geographical regions. However, these reports are largely from North America and Europe, and data from other countries are insufficient. In this multicenter study we aimed to identify the clinical characteristics of SMZL patients in Turkey, including viral hepatitis status and treatment details. Materials and Methods: Data were gathered from participating centers from different regions of Turkey using IBM SPSS Statistics 23 for Windows. Hepatitis B virus surface antigen (HBsAg), anti-HBs antibody, anti-HB core antigen antibody (anti-HBcAg), HB viral load, anti-hepatitis C virus (HCV) antibody, HCV viral load results were analyzed. Results: One hundred and four patients were reported. Hepatitis C virus positivity was observed in only one patient. However, hepatitis B virus surface antigen (HBsAg) positivity was observed in 11.2% and HBsAg and/or anti-HB core antigen antibody (anti-HBcAg) positivities were seen in 34.2% of the patients. The median age was 60 years (range=35-87). Median follow-up duration was 21.2 months (range=00.2-212; 23.2 months for surviving patients). Median overall survival was not reached. Estimated 3-year and 10-year survival rates were 84.8% and 68.9%, respectively. Older age, no splenectomy during follow-up, platelet count of
Amaç: Splenik marjinal zon lenfoma’yı da (SMZL) içeren ekstranodal marjinal zon lenfomaların patogenezinde, kronik antijenik stimülasyon sorumlu olan mekanizmadır. Bazı coğrafik bölgelerde SMZL hastalarında kronik hepatit C sıklıkla gözlenir. Fakat bu çalışmalar sıklıkla kuzey Amerika ve Avrupa’dandır. Diğer ülkelerden veriler sınırlıdır. Bu çalışma ile Türkiye’deki SMZL hastalarının hepatit serolojisi durumları ve tedavi yöntemlerinin ortaya konulması amaçlanmıştır. Gereç ve Yöntemler: Türkiye’de farklı merkezlerden IBM SPSS Statistics for Windows v23 elektronik tablo kullanılarak veriler toplanmıştır. Hepatit B virüs yüzey antijeni (HBsAg), Anti-HBs antikor, Anti-HB kor antijen antikoru (anti-HBcAg), HB virüs yükü, anti-hepatit C virüs (HCV) antikoru, HCV virüs yükü sonuçları analiz edilmiştir. Bulgular: Yüz dört hastanın verilerine ulaşılmıştır. Hepatit C virüs pozitifliği sadece 1 hastada tespit edilmiştir. Hepatit B virüs yüzey antijeni (HBsAg) pozitifliği %11,2, HBsAg ve/veya hepatit B kor antijen antikoru (anti-HBcAg) pozitifliği %34,2 oranında tespit edilmiştir. Ortanca yaş 60 yıl (35-87) olarak saptanmıştır. Ortanca izlem süresi 21,2 (0,2-212) ay (yaşayan hastalar için 23,2 ay) olarak bulunmuştur. Ortanca genel sağkalım (GS) süresine ulaşılamamıştır. Tahmini 3-yıl ve 10-yıl GS oranları %84,8 ve %68,9 olarak bulunmuştur. İleri yaş, splenektomi yapılmaması
Databáze: OpenAIRE
Externí odkaz: